A small subset of pituitary adenomas grows despite maximal treatment with standard therapies; namely, surgery and radiotherapy. These aggressive tumors demonstrate 2 patterns of growth: they may be locally aggressive or metastasize distantly, either hematogenously or through the spinal fluid. Further surgery and radiotherapy may be helpful for palliation of symptoms, but they are rarely definitive in the management of these malignant tumors. The only chemotherapy with established activity in the treatment of pituitary tumors is the alkylating agent temozolomide. At most, 50% of patients exhibit an objective response to temozolomide and the median time to progression is short; thus, there remains a significant unmet need for effective treatments within this patient population. Several targeted agents have reported activity in this tumor type-including small molecule inhibitors, checkpoint inhibitors, and other biologics-but remain investigational at this time.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566322PMC
http://dx.doi.org/10.1210/clinem/dgaa649DOI Listing

Publication Analysis

Top Keywords

surgery radiotherapy
8
approach treatment
4
treatment patient
4
patient aggressive
4
aggressive pituitary
4
pituitary tumor
4
tumor small
4
small subset
4
subset pituitary
4
pituitary adenomas
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!